Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) Profit After Tax (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Profit After Tax readings, the most recent being -$35.8 million for Q1 2026.

  • Quarterly Profit After Tax fell 19.14% to -$35.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$135.2 million through Mar 2026, down 1.77% year-over-year, with the annual reading at -$129.5 million for FY2025, 1.27% down from the prior year.
  • Profit After Tax hit -$35.8 million in Q1 2026 for Oric Pharmaceuticals, down from -$30.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$20.3 million in Q2 2022 and bottomed at -$36.4 million in Q2 2025.
  • Average Profit After Tax over 5 years is -$28.4 million, with a median of -$28.3 million recorded in 2023.
  • The largest annual shift saw Profit After Tax crashed 40.28% in 2022 before it increased 15.98% in 2025.
  • Oric Pharmaceuticals' Profit After Tax stood at -$20.8 million in 2022, then plummeted by 35.89% to -$28.3 million in 2023, then dropped by 28.16% to -$36.3 million in 2024, then grew by 15.98% to -$30.5 million in 2025, then dropped by 17.25% to -$35.8 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Profit After Tax are -$35.8 million (Q1 2026), -$30.5 million (Q4 2025), and -$32.6 million (Q3 2025).